233 related articles for article (PubMed ID: 29996906)
1. Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Wang C; Bai F; Zhang LH; Scott A; Li E; Pei XH
Breast Cancer Res; 2018 Jul; 20(1):74. PubMed ID: 29996906
[TBL] [Abstract][Full Text] [Related]
2. PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors.
Bai F; Liu S; Liu X; Hollern DP; Scott A; Wang C; Zhang L; Fan C; Fu L; Perou CM; Zhu WG; Pei XH
Breast Cancer Res; 2021 Jan; 23(1):10. PubMed ID: 33478572
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
Bai F; Chan HL; Scott A; Smith MD; Fan C; Herschkowitz JI; Perou CM; Livingstone AS; Robbins DJ; Capobianco AJ; Pei XH
Cancer Res; 2014 Nov; 74(21):6161-72. PubMed ID: 25239453
[TBL] [Abstract][Full Text] [Related]
4. GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
Bai F; Zhang LH; Liu X; Wang C; Zheng C; Sun J; Li M; Zhu WG; Pei XH
Theranostics; 2021; 11(17):8218-8233. PubMed ID: 34373738
[No Abstract] [Full Text] [Related]
5. Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathway.
Bai F; Wang C; Liu X; Hollern D; Liu S; Fan C; Liu C; Ren S; Herschkowitz JI; Zhu WG; Pei XH
Cell Death Dis; 2022 Mar; 13(3):195. PubMed ID: 35236825
[TBL] [Abstract][Full Text] [Related]
6. p16INK4a suppresses BRCA1-deficient mammary tumorigenesis.
Scott A; Bai F; Chan HL; Liu S; Ma J; Slingerland JM; Robbins DJ; Capobianco AJ; Pei XH
Oncotarget; 2016 Dec; 7(51):84496-84507. PubMed ID: 27811360
[TBL] [Abstract][Full Text] [Related]
7. Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.
Bai F; Smith MD; Chan HL; Pei XH
Oncogene; 2013 May; 32(22):2715-25. PubMed ID: 22777348
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing.
Sun H; Zeng J; Miao Z; Lei KC; Huang C; Hu L; Su SM; Chan UI; Miao K; Zhang X; Zhang A; Guo S; Chen S; Meng Y; Deng M; Hao W; Lei H; Lin Y; Yang Z; Tang D; Wong KH; Zhang XD; Xu X; Deng CX
Theranostics; 2021; 11(20):9967-9987. PubMed ID: 34815798
[No Abstract] [Full Text] [Related]
9. GATA3 functions downstream of BRCA1 to promote DNA damage repair and suppress dedifferentiation in breast cancer.
Wang X; Bai F; Liu X; Peng B; Xu X; Zhang H; Fu L; Zhu WG; Wang B; Pei XH
BMC Biol; 2024 Apr; 22(1):85. PubMed ID: 38627785
[TBL] [Abstract][Full Text] [Related]
10. CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis.
Pei XH; Bai F; Smith MD; Usary J; Fan C; Pai SY; Ho IC; Perou CM; Xiong Y
Cancer Cell; 2009 May; 15(5):389-401. PubMed ID: 19411068
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Estrogen Signaling Reduces the Incidence of
Baek HJ; Kim SE; Choi EK; Kim JK; Shin DH; Park EJ; Kim TH; Kim JY; Kim KG; Deng CX; Kim SS
Int J Biol Sci; 2018; 14(12):1755-1768. PubMed ID: 30416390
[TBL] [Abstract][Full Text] [Related]
12. Loss of function of GATA3 induces basal-like mammary tumors.
Bai F; Zheng C; Liu X; Chan HL; Liu S; Ma J; Ren S; Zhu WG; Pei XH
Theranostics; 2022; 12(2):720-733. PubMed ID: 34976209
[No Abstract] [Full Text] [Related]
13. Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers.
Zvelebil M; Oliemuller E; Gao Q; Wansbury O; Mackay A; Kendrick H; Smalley MJ; Reis-Filho JS; Howard BA
Breast Cancer Res; 2013 Mar; 15(2):R25. PubMed ID: 23506684
[TBL] [Abstract][Full Text] [Related]
14. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
[TBL] [Abstract][Full Text] [Related]
15. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
16. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
[TBL] [Abstract][Full Text] [Related]
17. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
18. p18INK4C and BRCA1 inhibit follicular cell proliferation and dedifferentiation in thyroid cancer.
Bai F; Liu X; Zhang X; Mao Z; Wen H; Ma J; Pei XH
Cell Cycle; 2023 Jul; 22(13):1637-1653. PubMed ID: 37345432
[TBL] [Abstract][Full Text] [Related]
19. Loss of function of GATA3 regulates FRA1 and c-FOS to activate EMT and promote mammary tumorigenesis and metastasis.
Liu X; Bai F; Wang Y; Wang C; Chan HL; Zheng C; Fang J; Zhu WG; Pei XH
Cell Death Dis; 2023 Jun; 14(6):370. PubMed ID: 37353480
[TBL] [Abstract][Full Text] [Related]
20. Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.
Suba Z
Recent Pat Anticancer Drug Discov; 2017; 12(2):136-147. PubMed ID: 28245776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
